Biological E’s Covid-19 vaccine Corbevax gets emergency use nod for children aged 12-18 years

new Delhi: Biologicals E Ltd’s COVID-19 vaccine Corbevax has received emergency use approval for children aged 12 and 18 in India. The Hyderabad-based pharmaceutical company was approved by the Drug Controller General of India (DCGI) on Monday.

“With this approval, we are close to ending our global fight against the COVID-19 pandemic. Once fully immunized, children can resume their activities and educational activities in schools and colleges without any apprehension,” said Mahima Dada, Managing Director, Biological E. Ltd said.

Corbevax, India’s third indigenous COVID-19 vaccine, will be given in two doses. In addition, this is the third vaccine approved for use in children 12 years of age and older, including Zydus Cadila’s DNA shot Zycov-D and Bharat Biotech’s Covaxin.

Earlier, the Corbevax vaccine had received approval from the Subject Expert Committee (SEC) of DCGI for emergency use authorization for those between 12 and 18 years of age.

Quoting official sources, ANI said the vaccine is expected to cost Rs 145 excluding taxes.

The approval is expected to further accelerate the ongoing vaccination campaign for children in the age group of 15 to 18 years and subsequently for children in the age group of 12 to 14 years.

On February 13, Biologicals E. Ltd had sought emergency use authorization of Corbevax, following which an expert panel of the Central Drugs Authority of India recommended its vaccine Corbevax to the Restricted Emergency Use Authority (EUA). The recommendation was then sent to the Drug Controller General of India (DCGI) for final approval.

First published:February 21, 2022, 6:51 pm

Leave a Reply